Joel Raskin

6.0k total citations · 2 hit papers
86 papers, 4.5k citations indexed

About

Joel Raskin is a scholar working on Pharmacology, Psychiatry and Mental health and Physiology. According to data from OpenAlex, Joel Raskin has authored 86 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Pharmacology, 44 papers in Psychiatry and Mental health and 22 papers in Physiology. Recurrent topics in Joel Raskin's work include Treatment of Major Depression (43 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (17 papers) and Pain Mechanisms and Treatments (11 papers). Joel Raskin is often cited by papers focused on Treatment of Major Depression (43 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (17 papers) and Pain Mechanisms and Treatments (11 papers). Joel Raskin collaborates with scholars based in United States, Canada and United Kingdom. Joel Raskin's co-authors include Yili Pritchett, Deborah N. D’Souza, Jeffrey L. Cummings, Joachim Wernicke, Donna E. Stewart, Fujun Wang, Smriti Iyengar, Craig Mallinckrodt, Sherie A. Dowsett and Paul Aisen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and American Journal of Psychiatry.

In The Last Decade

Joel Raskin

85 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

On the path to 2025: understanding the Alzheimer’s disease continuum

2017 369 citations Paul Aisen, Jeffrey L. Cummings et al. Alzheimer s Research & Therapy profile →
Drug development in Alzheimer’s disease: the path to 2025

2016 346 citations Jeffrey L. Cummings, Paul Aisen et al. Alzheimer s Research & Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joel Raskin United States	35	1.9k	1.7k	1.6k	743	638	86	4.5k
Jason T. Olin United States	34	1.3k 0.7×	1.3k 0.8×	2.5k 1.6×	243 0.3×	537 0.8×	79	5.1k
Rupert McShane United Kingdom	37	1.4k 0.8×	1.0k 0.6×	2.3k 1.5×	325 0.4×	595 0.9×	96	5.3k
Roger Lane United States	42	2.4k 1.3×	1.3k 0.8×	2.2k 1.4×	434 0.6×	562 0.9×	111	6.4k
Paul B. Rosenberg United States	42	902 0.5×	2.0k 1.2×	3.7k 2.4×	497 0.7×	1.3k 2.0×	174	7.2k
Jacobo Mintzer United States	40	1.3k 0.7×	1.3k 0.8×	3.7k 2.3×	232 0.3×	700 1.1×	137	6.0k
Anton P. Porsteinsson United States	37	1.3k 0.7×	2.4k 1.4×	3.0k 1.9×	242 0.3×	701 1.1×	129	5.9k
Prakash S. Masand United States	42	1.6k 0.8×	617 0.4×	2.5k 1.6×	477 0.6×	386 0.6×	225	5.5k
Neal R. Cutler United States	40	1.5k 0.8×	1.1k 0.6×	1.8k 1.2×	421 0.6×	863 1.4×	164	5.8k
Andrew Satlin United States	45	985 0.5×	1.9k 1.1×	2.1k 1.4×	855 1.2×	1.4k 2.2×	103	6.9k
Armin Szegedi Germany	40	1.3k 0.7×	442 0.3×	2.3k 1.5×	784 1.1×	551 0.9×	120	4.6k

Countries citing papers authored by Joel Raskin

Since Specialization

Citations

This map shows the geographic impact of Joel Raskin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Raskin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Raskin more than expected).

Fields of papers citing papers by Joel Raskin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Raskin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Raskin. The network helps show where Joel Raskin may publish in the future.

Co-authorship network of co-authors of Joel Raskin

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Raskin. A scholar is included among the top collaborators of Joel Raskin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Raskin. Joel Raskin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Raskin, Joel, Anita H. Clayton, Susan G. Kornstein, et al.. (2025). A phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder. Current Medical Research and Opinion. 41(9). 1723–1734.

Brandes, Jan Lewis, David Kudrow, Suzanne Klise, et al.. (2019). Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine Over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR) (P1.10-021). Neurology. 92(15_supplement). 2 indexed citations

Loo, Li Shen, Ira Turner, Michael Case, et al.. (2019). Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN). BMC Neurology. 19(1). 191–191. 24 indexed citations

Aisen, Paul, Jeffrey L. Cummings, Clifford R. Jack, et al.. (2017). On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimer s Research & Therapy. 9(1). 60–60. 369 indexed citations breakdown →

Lebrec, Jérémie, Haya Ascher‐Svanum, Yunfei Chen, et al.. (2016). Effect of diabetes on caregiver burden in an observational study of individuals with Alzheimer’s disease. BMC Geriatrics. 16(1). 93–93. 23 indexed citations

Liu‐Seifert, Hong, Eric Siemers, Katherine J. Selzler, et al.. (2016). CORRELATION BETWEEN COGNITION AND FUNCTION ACROSS THE SPECTRUM OF ALZHEIMER’S DISEASE. The Journal of Prevention of Alzheimer s Disease. 3(3). 1–7. 15 indexed citations

Liu‐Seifert, Hong, Eric Siemers, Karen Price, et al.. (2015). Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease. Journal of Alzheimer s Disease. 47(1). 205–214. 62 indexed citations

Rothschild, Anthony J., et al.. (2013). The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. Comprehensive Psychiatry. 55(1). 1–10. 51 indexed citations

Brnabic, Alan, et al.. (2012). Frequency and outcomes of painful physical symptoms in a naturalistic population with major depressive disorder: an analysis of pooled observational studies focusing on subjects aged 65 years and over. International Journal of Clinical Practice. 66(12). 1158–1167. 5 indexed citations

10.

McIntosh, Diane, Hengyuan Li, Nadia Hussain, et al.. (2010). Attributes of response in depressed patients switched to treatment with duloxetine. International Journal of Clinical Practice. 65(1). 73–81. 14 indexed citations

11.

Zhang, Mingyuan, Gang Wang, Hongyan Zhang, et al.. (2010). Association between painful physical symptoms and clinical outcomes in Chinese patients with major depressive disorder: a three-month observational study.. PubMed. 123(15). 2063–9. 9 indexed citations

12.

Wing, Yun Kwok, Ahmad Hatim Sulaiman, Nan‐Ying Chiu, et al.. (2009). Association between painful physical symptoms and clinical outcomes in East Asian patients with major depressive disorder: a 3-month prospective observational study. International Journal of Clinical Practice. 63(7). 1041–1049. 39 indexed citations

13.

Wise, Thomas N., et al.. (2007). The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. International Journal of Clinical Practice. 61(8). 1283–1293. 52 indexed citations

14.

Raskin, Joel, Curtis G. Wiltse, Alan P. Siegal, et al.. (2007). Efficacy of Duloxetine on Cognition, Depression, and Pain in Elderly Patients With Major Depressive Disorder: An 8-Week, Double-Blind, Placebo-Controlled Trial. American Journal of Psychiatry. 164(6). 900–909. 244 indexed citations

15.

Raskin, Joel, Jimmy Yu Xu, & Daniel K. Kajdasz. (2007). Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder. International Psychogeriatrics. 20(2). 309–327. 22 indexed citations

16.

Rynn, Moira A., James Russell, J. Erickson, et al.. (2007). Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depression and Anxiety. 25(3). 182–189. 112 indexed citations

17.

Pérahia, David, et al.. (2006). Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics. International Clinical Psychopharmacology. 21(5). 285–295. 15 indexed citations

18.

Pérahia, David, Daniel K. Kajdasz, Daniel Walker, Joel Raskin, & André Tylee. (2006). Duloxetine 60 mg once daily in the treatment of milder major depressive disorder. International Journal of Clinical Practice. 60(5). 613–620. 23 indexed citations

19.

Raskin, Joel, Fujun Wang, Yili Pritchett, & D. Goldstein. (2006). Duloxetine for Patients with Diabetic Peripheral Neuropathic Pain: A 6-Month Open-Label Safety Study. Pain Medicine. 7(5). 373–385. 73 indexed citations

20.

Mallinckrodt, Craig, Joel Raskin, Madelaine M. Wohlreich, John G. Watkin, & Michael J. Detke. (2004). The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. BMC Psychiatry. 4(1). 26–26. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact